Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1340069

Cover Image

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1340069

Small Molecule Innovator CDMO Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 6500
PDF (Enterprise License)
USD 9000

Add to Cart

Description

Table of Contents

List of Tables

The small molecule innovator contract development and manufacturing organization (CDMO) market is expected to experience a CAGR of 6.5% during the forecast period of 2023 to 2031, due to the increasing demand for outsourcing pharmaceutical development and manufacturing services. Small molecule drugs remain a dominant class of therapeutics, and innovative pharmaceutical companies are increasingly relying on CDMOs to accelerate drug development timelines, access specialized expertise, and optimize manufacturing processes. The market revenue for small molecule innovator CDMOs has witnessed substantial expansion, driven by the rising number of small molecule drug candidates in the development pipeline and the complexity of drug development programs that require specialized infrastructure and capabilities. Furthermore, advancements in pharmaceutical research and the expanding range of therapeutic areas are driving the demand for specialized services, such as high-potency active pharmaceutical ingredient (HPAPI) synthesis, bioconjugation, and continuous manufacturing. Small molecule innovator CDMOs with the technical expertise and regulatory compliance to handle these challenging projects are in high demand, contributing to the market's growth.

Increasing Demand for Outsourcing Services in Drug Development

The growing demand for outsourcing services in drug development is a significant driver of the Small Molecule Innovator CDMO market. Pharmaceutical companies are increasingly focusing on their core competencies of drug discovery and clinical development, leading them to outsource the complex and resource-intensive processes of drug substance synthesis and drug product manufacturing to CDMOs. This trend is supported by a study published in the Journal of Pharmaceutical Innovation, which highlights the benefits of outsourcing in terms of cost efficiency, access to specialized expertise, and accelerated timelines. CDMOs offer a range of services, from early-stage development to commercial manufacturing, providing pharmaceutical companies with a flexible and cost-effective approach to drug development.

Advancements in Pharmaceutical Research and Development

Advancements in pharmaceutical research and development have fueled the demand for specialized services, driving the growth of the Small Molecule Innovator CDMO market. The pharmaceutical industry is continuously exploring novel therapeutic areas, including personalized medicine, targeted therapies, and high-potency drugs. These advancements often require specialized capabilities, such as high-potency active pharmaceutical ingredient (HPAPI) synthesis and bioconjugation, which CDMOs are well-equipped to handle. According to a report by the American Association of Pharmaceutical Scientists (AAPS), CDMOs play a crucial role in providing the necessary technical expertise and infrastructure to support the development of these complex drug candidates.

Need for Agile and Flexible Manufacturing Capabilities

The need for agile and flexible manufacturing capabilities is driving pharmaceutical companies to seek the services of Small Molecule Innovator CDMOs. The COVID-19 pandemic highlighted the importance of adaptability in pharmaceutical manufacturing to respond to sudden changes in demand and supply chain disruptions. CDMOs with diverse manufacturing capabilities, including continuous manufacturing processes, are better positioned to meet these challenges. A study published in the Journal of Pharmaceutical Sciences emphasizes the potential benefits of continuous manufacturing, such as reduced production times and enhanced process control. As a result, pharmaceutical companies are increasingly partnering with CDMOs to leverage their expertise in implementing agile and flexible manufacturing strategies.

Intellectual Property and Confidentiality Concerns

One significant restraint in the Small Molecule Innovator CDMO market is related to intellectual property (IP) and confidentiality concerns. Pharmaceutical companies often work on proprietary drug compounds that are critical to their competitive advantage and market position. When outsourcing drug development and manufacturing to CDMOs, there is a risk of IP infringement or leakage of confidential information, leading to potential legal and reputational consequences. According to a study published in the European Journal of Pharmaceutical Sciences, maintaining the confidentiality of client's proprietary information is a crucial challenge faced by CDMOs. Moreover, the potential for knowledge transfer during the outsourcing process can raise concerns among pharmaceutical companies, especially for complex and novel drug candidates. As a result, some innovative pharmaceutical companies may be hesitant to fully engage with CDMOs and may choose to keep certain aspects of their drug development in-house to safeguard their intellectual property rights. To address this restraint, CDMOs must implement robust confidentiality agreements, data security measures, and stringent IP protection protocols. Building trust with their clients by demonstrating a strong commitment to safeguarding sensitive information can help mitigate these concerns and foster long-term partnerships in the Small Molecule Innovator CDMO market.

Small Molecule API Segment to Lead the Growth Among Other Product Types

The small molecule API segment is expected to demonstrate the highest CAGR during the forecast period of 2023 to 2031. Small Molecule APIs are the chemical compounds that form the core therapeutic component of a drug and are essential for its pharmacological activity. The increasing demand for innovative drug candidates and the complexity of small-molecule drug development have driven pharmaceutical companies to outsource API synthesis to CDMOs. These CDMOs offer specialized expertise in complex synthesis routes, process optimization, and compliance with stringent regulatory standards. Additionally, advancements in technology, such as continuous flow chemistry, have further contributed to the growth of the Small Molecule API segment. On the other hand, the Small Molecule Drug Product segment holds the highest revenue percentage in the market. Small Molecule Drug Products refer to the final dosage forms of the drug, such as tablets, capsules, and injectables, that are ready for administration to patients. The high revenue in this segment is attributed to the commercial-scale manufacturing of drug products and the complex manufacturing processes involved. CDMOs specializing in drug product manufacturing offer a range of services, including formulation development, aseptic filling, and lyophilization, to meet the diverse needs of pharmaceutical companies. As the demand for personalized medicine and targeted therapies increases, the Small Molecule Drug Product segment is expected to maintain its revenue growth. Overall, the Small Molecule Innovator CDMO market benefits from the synergy between the Small Molecule API and Small Molecule Drug Product segments, with the Small Molecule API segment driving the CAGR and the Small Molecule Drug Product segment contributing to the highest revenue percentage. CDMOs offering comprehensive services across both segments are well-positioned to capitalize on the opportunities in the evolving pharmaceutical landscape.

Biotechnology Companies to Lead the Growth Among Others in Customer Type Segment

In the Small Molecule Innovator CDMO market, the customer type segment comprises two primary categories: Pharmaceutical companies and Biotechnology companies. Among these, Biotechnology companies are expected to demonstrate the highest CAGR during the forecast period of 2023 to 2031. Biotechnology companies are increasingly contributing to drug development pipelines, with a focus on novel and targeted therapies. The complexity of these therapies often requires specialized expertise and infrastructure, driving Biotechnology companies to seek the services of CDMOs for small-molecule drug development and manufacturing. Additionally, the rising number of biopharmaceutical startups and the need to conserve capital have further fueled the demand for CDMO services among Biotechnology companies. On the other hand, Pharmaceutical companies hold the highest revenue percentage in the market. Established Pharmaceutical companies with a diverse portfolio of small molecule drugs often outsource specific drug development projects or manufacturing processes to CDMOs to optimize resource allocation and reduce time-to-market. The high revenue in this segment is attributed to the volume of projects and commercial-scale manufacturing associated with Pharmaceutical companies. As the trend of outsourcing drug development and manufacturing continues to grow, both customer segments are expected to present significant opportunities for CDMOs. The Biotechnology segment is likely to experience continued growth, driven by the increasing focus on innovative therapies, while the Pharmaceutical segment will remain a key revenue generator due to its established presence and wide-ranging requirements. CDMOs that offer tailored solutions to meet the distinct needs of both customer segments are poised to thrive in the competitive Small Molecule Innovator CDMO market.

APAC to Promise Significant Opportunities during the Forecast Period

North America and Europe have traditionally been dominant players in the market, collectively holding a substantial revenue percentage. The United States and Western European countries, such as Germany and the United Kingdom, are major contributors to the revenue due to their well-established pharmaceutical and biotechnology industries, advanced healthcare infrastructure, and strong focus on drug innovation. However, these regions are witnessing moderate CAGR as they approach market saturation and mature. On the other hand, the Asia-Pacific region is expected to experience the highest CAGR in the Small Molecule Innovator CDMO market during the forecast period of 2023 to 2031. Countries such as China, India, and Japan are witnessing rapid growth due to several factors. The region's large population base, increasing prevalence of chronic diseases, and growing healthcare expenditure are driving pharmaceutical and biotechnology companies to outsource drug development and manufacturing to CDMOs. Moreover, the presence of skilled and cost-effective labor in the region is attracting global CDMOs to establish manufacturing facilities, further propelling the market's growth.

Market Competition to Intensify during the Forecast Period

The Small Molecule Innovator CDMO market is characterized by intense competition, with several top players vying for market share and leadership positions. Some of the key players in the industry include Lonza Group AG, Catalent, Inc., Patheon (now part of Thermo Fisher Scientific), Recipharm AB, and Cambrex Corporation. These companies are at the forefront of providing comprehensive small molecule development and manufacturing services to pharmaceutical and biotechnology companies globally. The competitive trends in the Small Molecule Innovator CDMO market are centered around innovation, expansion, strategic partnerships, and a customer-centric approach. To maintain their competitive edge, top players are heavily investing in research and development to enhance their capabilities and offer cutting-edge solutions. They focus on optimizing their manufacturing processes, adopting advanced technologies, and expanding their service offerings to cater to the evolving needs of their clients. Expansion and geographical diversification are also prominent strategies employed by these companies. They are establishing new facilities in strategic locations to tap into emerging markets and cater to the regional demand for outsourcing services. Additionally, strategic acquisitions and collaborations are common among top players to gain access to specialized expertise and broaden their service portfolio. For instance, Lonza's acquisition of Capsugel and Catalent's acquisition of Cook Pharmica is illustrative of these strategies, enabling these companies to provide end-to-end solutions to their clients.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofSmall Molecule Innovator CDMO market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Small Molecule Innovator CDMO market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

  • Small Molecule API
  • Small Molecule Drug Product
    • Oral solid dose
    • Semi-Solid Dose
    • Liquid Dose
    • Others

Stage Type

  • Preclinical
  • Clinical
    • Phase I
    • Small
    • Medium
    • Large
  • Phase II
    • Small
    • Medium
    • Large
  • Phase III
    • Small
    • Medium
    • Large
  • Commercial

Customer Type

  • Pharmaceutical
    • Small
    • Medium
    • Large
  • Biotechnology

Therapeutic Area

  • Cardiovascular disease
  • Oncology
  • Respiratory disorders
  • Neurology
  • Metabolic disorders
  • Infectious disease
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Small Molecule Innovator CDMO market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Small Molecule Innovator CDMO market?
  • Which is the largest regional market for Small Molecule Innovator CDMO market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Small Molecule Innovator CDMO market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Small Molecule Innovator CDMO market worldwide?
Show more
Product Code: 139753-07-23

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Small Molecule Innovator CDMO Market
  • 2.2. Global Small Molecule Innovator CDMO Market, By Product, 2022 (US$ Million)
  • 2.3. Global Small Molecule Innovator CDMO Market, By Stage Type, 2022 (US$ Million)
  • 2.4. Global Small Molecule Innovator CDMO Market, By Customer Type, 2022 (US$ Million)
  • 2.5. Global Small Molecule Innovator CDMO Market, By Therapeutic Area, 2022 (US$ Million)
  • 2.6. Global Small Molecule Innovator CDMO Market, By Geography, 2022 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2022

3. Small Molecule Innovator CDMO Market: Competitive Analysis

  • 3.1. Market Positioning of Key Small Molecule Innovator CDMO Market Vendors
  • 3.2. Strategies Adopted by Small Molecule Innovator CDMO Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Small Molecule Innovator CDMO Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Small Molecule Innovator CDMO Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Small Molecule API
    • 5.3.2. Small Molecule Drug Product
      • 5.3.2.1. Oral solid dose
      • 5.3.2.2. Semi-Solid Dose
      • 5.3.2.3. Liquid Dose
      • 5.3.2.4. Others

6. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Preclinical
    • 6.3.2. Clinical
      • 6.3.2.1. Phase I
        • 6.3.2.1.1. Small
        • 6.3.2.1.2. Medium
        • 6.3.2.1.3. Large
      • 6.3.2.2. Phase II
        • 6.3.2.2.1. Small
        • 6.3.2.2.2. Medium
        • 6.3.2.2.3. Large
      • 6.3.2.3. Phase III
        • 6.3.2.3.1. Small
        • 6.3.2.3.2. Medium
        • 6.3.2.3.3. Large
    • 6.3.3. Commercial

7. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Pharmaceutical
      • 7.3.1.1. Small
      • 7.3.1.2. Medium
      • 7.3.1.3. Large
    • 7.3.2. Biotechnology

8. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Cardiovascular disease
    • 8.3.2. Oncology
    • 8.3.3. Respiratory disorders
    • 8.3.4. Neurology
    • 8.3.5. Metabolic disorders
    • 8.3.6. Infectious disease
    • 8.3.7. Others

9. North America Small Molecule Innovator CDMO Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
  • 9.3. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
  • 9.4. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
  • 9.5. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
  • 9.6.Small Molecule Innovator CDMO Market: By Region, 2021-2031, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 9.6.1.1.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 9.6.1.1.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 9.6.1.1.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 9.6.1.2.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 9.6.1.2.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 9.6.1.2.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 9.6.1.3.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 9.6.1.3.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 9.6.1.3.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

10. UK and European Union Small Molecule Innovator CDMO Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
  • 10.3. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
  • 10.4. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
  • 10.5. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
  • 10.6.Small Molecule Innovator CDMO Market: By Region, 2021-2031, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.1.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.1.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.1.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.2.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.2.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.2.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.3.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.3.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.3.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.4.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.4.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.4.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.5.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.5.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.5.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 10.6.1.6.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 10.6.1.6.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 10.6.1.6.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

11. Asia Pacific Small Molecule Innovator CDMO Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
  • 11.3. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
  • 11.4. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
  • 11.5. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
  • 11.6.Small Molecule Innovator CDMO Market: By Region, 2021-2031, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.1.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.1.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.1.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.2.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.2.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.2.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.3.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.3.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.3.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.4.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.4.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.4.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.5.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.5.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.5.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 11.6.1.6.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 11.6.1.6.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 11.6.1.6.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

12. Latin America Small Molecule Innovator CDMO Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
  • 12.3. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
  • 12.4. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
  • 12.5. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
  • 12.6.Small Molecule Innovator CDMO Market: By Region, 2021-2031, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 12.6.1.1.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 12.6.1.1.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 12.6.1.1.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 12.6.1.2.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 12.6.1.2.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 12.6.1.2.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 12.6.1.3.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 12.6.1.3.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 12.6.1.3.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

13. Middle East and Africa Small Molecule Innovator CDMO Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
  • 13.3. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
  • 13.4. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
  • 13.5. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
  • 13.6.Small Molecule Innovator CDMO Market: By Region, 2021-2031, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 13.6.1.1.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 13.6.1.1.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 13.6.1.1.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 13.6.1.2.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 13.6.1.2.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 13.6.1.2.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Small Molecule Innovator CDMO Market: By Product, 2021-2031, USD (Million)
        • 13.6.1.3.2. Small Molecule Innovator CDMO Market: By Stage Type, 2021-2031, USD (Million)
        • 13.6.1.3.3. Small Molecule Innovator CDMO Market: By Customer Type, 2021-2031, USD (Million)
        • 13.6.1.3.4. Small Molecule Innovator CDMO Market: By Therapeutic Area, 2021-2031, USD (Million)

14. Company Profile

  • 14.1. Lonza Group AG
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. Catalent, Inc.
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. Thermo Fisher Scientific
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Recipharm AB
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Cambrex Corporation
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Piramal Pharma Solutions
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. CordenPharma International
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. Wuxi AppTec
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. Cambrex Corporation
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Siegfried Holding AG
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. Boehringer Ingelheim
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. Labcorp Drug Development
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. Other Notable Players
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
Show more
Product Code: 139753-07-23

List of Tables

  • TABLE 1 Global Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 2 Global Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 3 Global Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 4 Global Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 5 Global Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 6 Global Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 7 Global Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 8 Global Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 9 Global Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 10 Global Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 11 North America Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 12 North America Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 13 North America Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 14 North America Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 15 North America Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 16 North America Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 17 North America Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 18 North America Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 19 North America Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 20 North America Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 21 U.S. Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 22 U.S. Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 23 U.S. Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 24 U.S. Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 25 U.S. Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 26 U.S. Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 27 U.S. Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 28 U.S. Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 29 U.S. Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 30 U.S. Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 31 Canada Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 32 Canada Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 33 Canada Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 34 Canada Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 35 Canada Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 36 Canada Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 37 Canada Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 38 Canada Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 39 Canada Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 40 Canada Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 41 Rest of North America Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 42 Rest of North America Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 43 Rest of North America Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 44 Rest of North America Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 45 Rest of North America Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 46 Rest of North America Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 47 Rest of North America Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 48 Rest of North America Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 49 Rest of North America Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 50 Rest of North America Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 51 UK and European Union Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 52 UK and European Union Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 53 UK and European Union Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 54 UK and European Union Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 55 UK and European Union Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 56 UK and European Union Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 57 UK and European Union Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 58 UK and European Union Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 59 UK and European Union Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 60 UK and European Union Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 61 UK Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 62 UK Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 63 UK Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 64 UK Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 65 UK Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 66 UK Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 67 UK Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 68 UK Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 69 UK Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 70 UK Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 71 Germany Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 72 Germany Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 73 Germany Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 74 Germany Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 75 Germany Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 76 Germany Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 77 Germany Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 78 Germany Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 79 Germany Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 80 Germany Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 81 Spain Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 82 Spain Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 83 Spain Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 84 Spain Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 85 Spain Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 86 Spain Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 87 Spain Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 88 Spain Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 89 Spain Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 90 Spain Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 91 Italy Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 92 Italy Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 93 Italy Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 94 Italy Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 95 Italy Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 96 Italy Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 97 Italy Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 98 Italy Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 99 Italy Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 100 Italy Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 101 France Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 102 France Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 103 France Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 104 France Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 105 France Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 106 France Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 107 France Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 108 France Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 109 France Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 110 France Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 111 Rest of Europe Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 112 Rest of Europe Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 113 Rest of Europe Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 114 Rest of Europe Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 115 Rest of Europe Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 116 Rest of Europe Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 117 Rest of Europe Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 118 Rest of Europe Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 119 Rest of Europe Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 120 Rest of Europe Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 121 Asia Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 122 Asia Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 123 Asia Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 124 Asia Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 125 Asia Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 126 Asia Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 127 Asia Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 128 Asia Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 129 Asia Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 130 Asia Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 131 China Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 132 China Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 133 China Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 134 China Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 135 China Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 136 China Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 137 China Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 138 China Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 139 China Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 140 China Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 141 Japan Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 142 Japan Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 143 Japan Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 144 Japan Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 145 Japan Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 146 Japan Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 147 Japan Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 148 Japan Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 149 Japan Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 150 Japan Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 151 India Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 152 India Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 153 India Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 154 India Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 155 India Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 156 India Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 157 India Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 158 India Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 159 India Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 160 India Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 161 Australia Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 162 Australia Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 163 Australia Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 164 Australia Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 165 Australia Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 166 Australia Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 167 Australia Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 168 Australia Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 169 Australia Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 170 Australia Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 171 South Korea Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 172 South Korea Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 173 South Korea Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 174 South Korea Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 175 South Korea Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 176 South Korea Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 177 South Korea Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 178 South Korea Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 179 South Korea Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 180 South Korea Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 181 Latin America Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 182 Latin America Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 183 Latin America Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 184 Latin America Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 185 Latin America Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 186 Latin America Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 187 Latin America Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 188 Latin America Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 189 Latin America Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 190 Latin America Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 191 Brazil Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 192 Brazil Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 193 Brazil Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 194 Brazil Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 195 Brazil Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 196 Brazil Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 197 Brazil Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 198 Brazil Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 199 Brazil Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 200 Brazil Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 201 Mexico Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 202 Mexico Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 203 Mexico Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 204 Mexico Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 205 Mexico Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 206 Mexico Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 207 Mexico Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 208 Mexico Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 209 Mexico Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 210 Mexico Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 211 Rest of Latin America Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 212 Rest of Latin America Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 213 Rest of Latin America Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 214 Rest of Latin America Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 215 Rest of Latin America Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 216 Rest of Latin America Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 217 Rest of Latin America Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 218 Rest of Latin America Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 219 Rest of Latin America Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 220 Rest of Latin America Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 221 Middle East and Africa Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 222 Middle East and Africa Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 223 Middle East and Africa Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 224 Middle East and Africa Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 225 Middle East and Africa Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 226 Middle East and Africa Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 227 Middle East and Africa Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 228 Middle East and Africa Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 229 Middle East and Africa Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 230 Middle East and Africa Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 231 GCC Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 232 GCC Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 233 GCC Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 234 GCC Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 235 GCC Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 236 GCC Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 237 GCC Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 238 GCC Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 239 GCC Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 240 GCC Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 241 Africa Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 242 Africa Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 243 Africa Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 244 Africa Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 245 Africa Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 246 Africa Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 247 Africa Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 248 Africa Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 249 Africa Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 250 Africa Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

  • TABLE 251 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Product, 2021-2031, USD (Million)
  • TABLE 252 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Small Molecule Drug Product, 2021-2031, USD (Million)

TABLE 253 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Stage Type, 2021-2031, USD (Million)

  • TABLE 254 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Clinical, 2021-2031, USD (Million)

TABLE 255 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Phase I, 2021-2031, USD (Million)

TABLE 256 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Phase II, 2021-2031, USD (Million)

TABLE 257 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Phase III, 2021-2031, USD (Million)

TABLE 258 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Customer Type, 2021-2031, USD (Million)

  • TABLE 259 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Pharmaceutical, 2021-2031, USD (Million)

TABLE 260 Rest of Middle East and Africa Small Molecule Innovator CDMO Market By Therapeutic Area, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Small Molecule Innovator CDMO Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Small Molecule Innovator CDMO Market: Quality Assurance
  • FIG. 5 Global Small Molecule Innovator CDMO Market, By Product, 2022
  • FIG. 6 Global Small Molecule Innovator CDMO Market, By Stage Type, 2022
  • FIG. 7 Global Small Molecule Innovator CDMO Market, By Customer Type, 2022
  • FIG. 8 Global Small Molecule Innovator CDMO Market, By Therapeutic Area, 2022
  • FIG. 9 Global Small Molecule Innovator CDMO Market, By Geography, 2022
  • FIG. 10 Market Geographical Opportunity Matrix - Global Small Molecule Innovator CDMO Market, 2022

FIG. 11Market Positioning of Key Small Molecule Innovator CDMO Market Players, 2022

FIG. 12Global Small Molecule Innovator CDMO Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 13 Global Small Molecule Innovator CDMO Market, By Product, 2022 Vs 2031, %
  • FIG. 14 Global Small Molecule Innovator CDMO Market, By Stage Type, 2022 Vs 2031, %
  • FIG. 15 Global Small Molecule Innovator CDMO Market, By Customer Type, 2022 Vs 2031, %
  • FIG. 16 Global Small Molecule Innovator CDMO Market, By Therapeutic Area, 2022 Vs 2031, %
  • FIG. 17 U.S. Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 18 Canada Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of North America Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 20 UK Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 21 Germany Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 22 Spain Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 23 Italy Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 24 France Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Europe Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 26 China Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 27 Japan Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 28 India Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 29 Australia Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 30 South Korea Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Asia Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 32 Brazil Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 33 Mexico Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 34 Rest of Latin America Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 35 GCC Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 36 Africa Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
  • FIG. 37 Rest of Middle East and Africa Small Molecule Innovator CDMO Market (US$ Million), 2021 - 2031
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!